Opinion
Video
This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.
Challenges and Opportunity With MRI
Ahmed Obeidat, MD, PhD, recounts the difficulties with MRI as a main biomarker for MS and shares strategies for optimal use of the technology.
Mark Freedman, MD, MSc, questions Ahmed Obeidat, MD, PhD, on his satisfaction with MRI as the primary biomarker for multiple sclerosis (MS) and how variability, cost, and limitations in conventional MRI impact clinical monitoring. Ahmed Obeidat, MD, PhD, acknowledges the challenges and highlights the reduced frequency of ordering MRIs, especially for stable patients on highly effective therapies.
Expressing dissatisfaction with the limited utility of conventional MRI for monitoring, Ahmed Obeidat, MD, PhD, emphasizes the importance of advanced MRI techniques, mentioning volume metrics, central vein sign, and normally appearing white matter. He discusses the need for quantitative biomarkers, expressing interest in fluid biomarkers for their potential in providing additional information beyond conventional MRIs.
Ahmed Obeidat, MD, PhD, advocates for combining imaging and fluid biomarkers in clinical practice for a more comprehensive understanding of the disease. He underscores the value of a quantitative biomarker, stating it could enhance patient comprehension and aid in assessing disease control.
Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.
